तुलना करने के लिए मीट्रिक्स | BLRX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधBLRXपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −1.3x | −0.4x | −0.2x | |
PEG अनुपात | −0.03 | 0.02 | 0.00 | |
क़ीमत/बुक | 0.7x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 6.8x | 3.0x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 186.7% | 60.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 6.3% | 7.8% | अनलॉक करें |
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.